EGM
IMDX

Engineers Gate Manager’s Insight Molecular Diagnostics IMDX Stock Holding History

Engineers Gate Manager’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.9K Buy
+18,253
New +$106K ﹤0.01% 2074
2022
Q3 		– Sell
-857
Closed -$15K – 1949
2022
Q2 		$15K Buy
+857
New +$19.5K ﹤0.01% 1831

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Engineers Gate Manager's IMDX Position: Q1 2026 in Review

Engineers Gate Manager opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 18,253 shares worth $59.9K. The stake represents ﹤0.01% of the portfolio and ranks #2074 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in IMDX as recently as Q2 2022.

Engineers Gate Manager first reported a position in IMDX in Q2 2022 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Engineers Gate Manager held 18,253 shares of Insight Molecular Diagnostics worth $59.9K as of Q1 2026.
  • Insight Molecular Diagnostics was a new Engineers Gate Manager position in Q1 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #2074 holding.
  • Engineers Gate Manager first reported a position in Insight Molecular Diagnostics in Q2 2022 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.